Browsing Tag
YORVIPATH
2 posts
MBX Biosciences stock surges 160% after Canvuparatide Phase 2 success in hypoparathyroidism
MBX Biosciences (NASDAQ: MBX) jumps 160% after Canvuparatide Phase 2 success in hypoparathyroidism; see trial data, stock reaction, and Phase 3 outlook.
Ascendis Pharma bags YORVIPATH FDA approval for adult hypoparathyroidism
In a landmark decision, the U.S. Food and Drug Administration (FDA) has granted approval to Ascendis Pharma A/S’s…